Examination about the efficacy and safety of abatacept iv in rheumatoid arthritis

Examination about the efficacy and safety of abatacept iv in rheumatoid arthritis - Examination for effectiveness with the intervention time of abatacept therapy in rheumatoid arthritis.(ORIB study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019262

Enrollment

Registered

2015-10-07

Start date

2011-03-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatoid arthritis with MTX-inadequate response and bio-naive

Exclusion criteria

Exclusion criteria: patients with no MTX treatment past biological agents' user

Design outcomes

Primary

Measure	Time frame
Clinical Remission Rate at week 48 Treatment reactivity by disease activity at week 48. Safety in this study period.	—

Secondary

Measure	Time frame
modified total sharp score at week48 J-HAQ at week 48 Disease activity score	—

Countries

Japan

Contacts

Public ContactTakafumi Hagiwara

Takarazuka city hospital Division of rheumatology

college@katzenauge.sakura.ne.jp0797871161

Outcome results